当前位置: 首页 » 资讯 » 行业动态 » 正文

SAG研究进展

发布日期:2017-11-23   浏览次数:4
核心提示:ahref=https://www.medchemexpress.com/SAG.htmlSAG/a产品描述:SAGisapotentbSmoreceptor/bagonist,andactivatestheHedgehogsi

                                                                                                                            NCT00700206
                                            Telik
                                            Myelodysplastic Syndrome (MDS)
                                            May 2008
                                            Phase 2
                                                                                                                                                                                                            NCT00280631
                                            Telik
                                            Myelodysplastic Syndrome (MDS)
                                            February 2006
                                            Phase 1-Phase 2
                                                                                                                                                                                                            NCT00035867
                                            Telik
                                            Myelodysplastic Syndromes
                                            April 2002
                                            Phase 1-Phase 2
                                                                                                                                                                                                                                        View MoreCollapse                                                                                               
                                                                                        References
[1]. Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20.

 
 "目录号: HY-13634A
metabolic Enzyme/Protease            -               
Ezatiostat 是一种 glutathione 类似物,为谷胱甘肽 S-转移酶 P1-1 (GSTP1-1) 抑制剂。
Gutathione S-transferase
相关产品
Ezatiostat hydrochloride  -  
生物活性
Description
Ezatiostat is a glutathione analog inhibitor of glutathione S-transferase P1-1 (GSTP1-1).
                                                   
                                                                                                                            In Vitro
Ezatiostat causes dissociation of the enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN) complex, leading to JNK activation by phosphorylation. The therapeutic action of ezatiostat appears to include both proliferation of normal myeloid progenitors as well as apoptosis of the malignant clone[1].
                                                   
                                                                                                                            Clinical Trial
                                                                                                                                                                                                                                                                                                           NCT01422486
                                            Telik
                                            Myelodysplastic Syndrome (MDS)
                                            October 2011
                                            Phase 2
                                                                                                                                                                                                            NCT01459159
                                            Telik
                                            Myelodysplastic Syndrome (MDS)
                                            October 2011
                                            Phase 2
                                                                                                                                                                                                            NCT00909584
                                            Telik
                                            Severe Chronic Neutropenia
                                            April 2009
                                            Phase 2
                                                                                                                                                                                                            NCT01062152
                                            Telik
                                            Myelodysplastic Syndrome
                                            November 2009
                                            Phase 1
                                                                                                                                                                                                            NCT00701870
                                            Telik
                                            Non-small Cell Lung Cancer
                                            October 2008
                                            Phase 2